



(43) International Publication Date
26 July 2012 (26.07.2012)

(10) International Publication Number
WO 2012/097427 A1

(51) International Patent Classification:

A61K 31/192 (2006.01) *C07C 323/20* (2006.01)
A61K 31/196 (2006.01) *C07C 323/52* (2006.01)
A61K 31/22 (2006.01) *C07C 323/62* (2006.01)
A61P 35/00 (2006.01) *C07C 57/30* (2006.01)
C07C 217/84 (2006.01) *C07C 59/52* (2006.01)
C07C 229/18 (2006.01) *C07C 59/64* (2006.01)
C07C 229/42 (2006.01) *C07C 59/76* (2006.01)
C07C 229/60 (2006.01)

(21) International Application Number:

PCT/CA2011/001179

(22) International Filing Date:

26 October 2011 (26.10.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/407,069 27 October 2010 (27.10.2010) US

(71) Applicant (for all designated States except US): **PRO-METIC BIOSCIENCES INC.** [CA/CA]; 531, boulevard des Prairies, Building 15, Laval, Quebec H7V 1B7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GAGNON, Lyne** [CA/CA]; 1973, De la Victoire Street, Laval, Quebec H7M 3E5 (CA). **GROUX, Brigitte** [CA/CA]; 5078, Fabre Street, Montreal, Quebec H2J 3W4 (CA). **GEERTS, Lili-anne** [CA/CA]; 1857 Route de la Cité-des-Jeunes, J7T 2C2 (CA). **LAURIN, Pierre** [CA/CA]; 2250, Chemin Sunset, Ville Mont-Royal, Quebec H3R 2Y6 (CA). **PENNEY, Christopher** [CA/CA]; 12787, Joron Street, Pierrefonds, Quebec H8Z 3K7 (CA). **ZACHARIE, Boulos** [CA/CA];

3202 Honoré de Balzac Street, Laval, Quebec H7P 5Y3 (CA).

(74) Agent: **LECLAIRE, France**; Prometic Life Sciences Inc., 531, boulevard des Prairies, Building 15, Laval, Quebec H7V 1B7 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

(57) Abstract: New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I.1, Formula I.2, Formula IA, Formula IB, Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine, doxorubicin, daunorubicin, cyclophosphamide, busulfan, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, methotrexate, gemcitabine, cisplatin, carboplatin and chlorambucil.



WO 2012/097427 A1